Vivani Medical Inc. (VANI) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Vivani Medical Inc. (VANI)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

1.21

0.02 (1.68%)

At close: Jan 15, 2025, 3:59 PM

1.21

-0.05%

After-hours Jan 15, 2025, 04:20 PM EST

undefined% (undefined)

Bid	1.19
Market Cap	71.67M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.43
PE Ratio (ttm)	-2.81
Forward PE	n/a
Analyst	Buy

Ask	1.21
Volume	73,790
Avg. Volume (20D)	127,473
Open	1.19
Previous Close	1.19
Day's Range	1.19 - 1.23
52-Week Range	1.01 - 7.80
Beta	undefined

About VANI

Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California....

[Show more]

Industry Medical - Devices

Sector Healthcare

IPO Date Nov 19, 2014

Employees 36

Stock Exchange NASDAQ

Ticker Symbol VANI

Website https://www.vivani.com

Analyst Forecast

According to 1 analyst ratings, the average rating for VANI stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 147.93% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

10 months ago · Source

-26.78%

Vivani Medical shares are trading lower after the ... Unlock content with Pro Subscription

10 months ago · Source

+270.3%

Vivani Medical shares are trading higher after the company announced preclinical data on weight loss effects for NPM-115 and disclosed that semaglutide is the active pharmaceutical ingredient in NPM-139.

News

3 weeks ago · https://thefly.com

Vivani reports start of first human trial of GLP-1 implant, says H.C. Wainwright

H.C. Wainwright reiterates a Buy rating and $4 price target on Vivani Medical shares after the company announced that the first-in-human clinical trial of NPM-115, an exenatide implant based on the co...

3 weeks ago · businesswire.com

Vivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia

ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative biopharmaceutical company developing novel, ultra long-acting drug implants, today anno...

1 month ago · businesswire.com

Vivani Medical to Present at the Innovation in Obesity Therapeutics Summit West Coast

ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, ann...